Printer Friendly

STUDIES IN THE NEW ENGLAND JOURNAL OF MEDICINE SUGGEST LEAST EXPENSIVE CLOT-DISSOLVER OFFERS SURVIVAL BENEFIT TO ELDERLY AND SAFETY ADVANTAGE

STUDIES IN THE NEW ENGLAND JOURNAL OF MEDICINE SUGGEST LEAST EXPENSIVE CLOT-DISSOLVER OFFERS SURVIVAL BENEFIT TO ELDERLY AND SAFETY ADVANTAGE
 Today's New England Journal of Medicine includes two articles demonstrating the efficacy, and safety advantage, of streptokinase -- the lowest-priced thrombolytic agent. Given that the average cost per dose of streptokinase is $300 in the U.S., eight times less than that of alteplase/t-PA, this data should prove valuable for articles on the cost-effectiveness of thrombolytic therapy and geriatric treatment issues.
 "Cost Effectiveness of Thrombolytic Therapy with Streptokinase in Elderly Patients with Suspected Acute Myocardial Infarction," H.M. Krumholz, et al (manuscript on pp. 7-13). The authors conclude that the treatment with streptokinase offers;
 -- a potential of three lives saved for every 100 treated (a conservative mortality estimate of 21.4 percent receiving therapy compared to 24.4 percent without therapy)
 -- similarly favorable cost-effectiveness for an 80 year-old with suspected MI ($21,000 per year of life saved) as for patients five or 10 years younger ($22,400 and $21,600 per year of life saved, respectively)
 "The Risk of Stroke in Patients with Acute Myocardial Infarction after Thrombolytic and Antithrombotic Treatment," GISSI-2 and International Study Group (manuscript on pp.1-6), compares the safety and potential risk of stroke between thrombolytic agents (Kabikinase (R)/ streptokinase vs. alteplase/t-PA) and various antithrombotic regimens (including aspirin, heparin). Conclusions show:
 --"patients with acute myocardial infarction who receive thrombolytic therapy have a small risk of stroke"
 -- treatment with Kabikinase (streptokinase) resulted in a smaller risk of stroke as compared to treatment with alteplase/t-PA. Similar results were shown in the recent ISIS-3 study comparing duteplase/t-PA with streptokinase.
 This information is provided on behalf of Kabi Pharmacia. For additional information or prescribing information about Kabikinase, please refer to contact below.
 CONTACT: Beth Fisher, 212-886-3105, or Kathy Ondrick, 212-886-3123, both of GTFH Public Relations, for Kabi Pharmacia.
 -0- 7/2/92


CO: Kabi Pharmacia ST: IN: MTC SU: PDT

TQ-AH -- NY055 -- 6336 07/02/92 16:47 EDT
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Jul 2, 1992
Words:333
Previous Article:FLORIDA REGIONAL STOCK REPORT FOR THURSDAY, JULY 2
Next Article:CORIMON ELECTS PHILIPPE ERARD CHAIRMAN OF THE BOARD APPROVES DIVIDEND, INCREASES AUTHORIZED CAPITAL
Topics:


Related Articles
EXOSURF(R) NEONATAL(TM) LINKED TO INCREASED SURVIVAL IN LARGER INFANTS WITH RESPIRATORY DISTRESS SYNDROME
EXOSURF(R) NEONATAL(TM) LINKED TO INCREASED SURVIVAL IN LARGER INFANTS WITH RESPIRATORY DISTRESS SYNDROME
STUDY PROVIDES ADDITIONAL CONFIRMATION THAT AZT TREATMENT IMPROVES SURVIVAL OF PEOPLE WITH AIDS
DRUG INCREASES HEART ATTACK SURVIVAL, PREVENTS SECOND ATTACKS
Cost Effectiveness of Simvastatin Treatment to Lower Cholesterol Levels in Patients with Coronary Heart Disease
Link Shown Between Inflammation and Heart Attack New Implication for Aspirin
Journal Supports VA Reorganization.
Breast Cancer Patients Switched to Pfizer's AROMASIN Were More Likely to Remain Cancer Free, New Study Shows; Results from Pfizer-Sponsored Study...
Multimedia News Release - Breast Cancer Patients Switched to Pfizer's AROMASIN Were More Likely to Remain Cancer Free, New Study Shows; Results From...

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters